CSP - Certified Specialty Pharmacist Clinical Management: Immunology Questions and Answers — Questions and Answers
Question 1: A patient with rheumatoid arthritis, who has failed methotrexate monotherapy, is being started on a Janus kinase (JAK) inhibitor. Which of the following represents a class-wide black box warning for JAK inhibitors that the specialty pharmacist must counsel the patient on?
- New or worsening heart failure
- Increased risk of serious infections, malignancy, and thrombosis (Correct answer)
- Progressive multifocal leukoencephalopathy (PML)
- Severe infusion-related reactions
Correct answer: Increased risk of serious infections, malignancy, and thrombosis
The FDA has required a class-wide black box warning for Janus kinase (JAK) inhibitors used for chronic inflammatory conditions. This warning includes an increased risk of serious infections, malignancies (like lymphoma and lung cancer), major adverse cardiovascular events (MACE), and thrombosis. While other warnings exist for different drug classes, this specific combination of risks is characteristic of the JAK inhibitor class warning.
Question 2: A 45-year-old male with Crohn's disease is receiving an infliximab infusion at an infusion center. 15 minutes into the infusion, he complains of flushing, itching, and shortness of breath. The nurse stops the infusion. What is the most appropriate immediate next step?
- Administer epinephrine immediately
- Restart the infusion at a slower rate
- Administer intravenous corticosteroids and antihistamines (Correct answer)
- Obtain trough and anti-drug antibody levels
Correct answer: Administer intravenous corticosteroids and antihistamines
For a mild-to-moderate infusion-related reaction (IRR), the standard procedure is to stop the infusion and provide supportive care, which typically includes administering intravenous corticosteroids (e.g., methylprednisolone) and antihistamines (e.g., diphenhydramine). Epinephrine is reserved for severe, anaphylactic reactions. Restarting the infusion without treatment is inappropriate, and while lab levels are important for long-term management, they are not the immediate priority during an acute reaction.
Question 3: A specialty pharmacist is reviewing a new prescription for ocrelizumab for a patient with relapsing-remitting multiple sclerosis. Which of the following baseline screenings is essential before the patient can receive their first dose?
- Ophthalmologic exam including optical coherence tomography (OCT)
- Tuberculosis (TB) skin test or interferon-gamma release assay (IGRA)
- Hepatitis B virus (HBV) screening (Correct answer)
- Lipid panel and liver function tests (LFTs)
Correct answer: Hepatitis B virus (HBV) screening
Ocrelizumab is an anti-CD20 monoclonal antibody that can cause reactivation of hepatitis B virus (HBV), potentially leading to fulminant hepatitis, liver failure, and death. Therefore, screening for HBV (including HBsAg and anti-HBc) is required before the first dose. While other tests may be part of general wellness or monitoring for other drug classes, HBV screening is a specific and critical prerequisite for initiating ocrelizumab.
Question 4: Which of the following biologic DMARDs used for rheumatoid arthritis works by inhibiting T-cell activation through binding to CD80 and CD86?
- Adalimumab
- Rituximab
- Tocilizumab
- Abatacept (Correct answer)
Correct answer: Abatacept
Abatacept is a T-cell co-stimulation modulator. It selectively binds to CD80 and CD86 on antigen-presenting cells, thereby blocking the required co-stimulatory signal needed for T-cell activation. Adalimumab is a TNF-alpha inhibitor, rituximab is an anti-CD20 monoclonal antibody that depletes B-cells, and tocilizumab is an IL-6 receptor antagonist.
Question 5: A patient with severe plaque psoriasis has been stable on adalimumab for two years. They call the specialty pharmacy to report that their symptoms have been worsening over the last three months despite adherence to their injections. What is the most likely immunological reason for this secondary loss of response?
- Tachyphylaxis due to receptor downregulation
- Formation of anti-drug antibodies (ADAs) (Correct answer)
- Increased drug clearance due to metabolic changes
- Disease progression to a non-TNF-mediated pathway
Correct answer: Formation of anti-drug antibodies (ADAs)
A secondary loss of response to a tumor necrosis factor (TNF) inhibitor like adalimumab is often due to the development of anti-drug antibodies (ADAs). These antibodies can neutralize the drug's activity or increase its clearance, leading to subtherapeutic drug levels and reduced efficacy. Therapeutic drug monitoring to check for trough concentrations and ADA levels can help confirm this and guide subsequent treatment decisions.
Question 6: A specialty pharmacist is counseling a patient starting on an interleukin-6 (IL-6) inhibitor, such as tocilizumab or sarilumab, for rheumatoid arthritis. In addition to the risk of serious infections, which of the following laboratory parameters requires routine monitoring with this class of medication?
- Serum uric acid
- Creatine phosphokinase (CPK)
- Absolute neutrophil count (ANC) and liver function tests (LFTs) (Correct answer)
- Serum creatinine and BUN
Correct answer: Absolute neutrophil count (ANC) and liver function tests (LFTs)
Interleukin-6 (IL-6) inhibitors are associated with hematologic and hepatic adverse effects. Routine monitoring of the absolute neutrophil count (ANC) for neutropenia and liver function tests (LFTs) for transaminitis is required. Dose adjustments or discontinuation may be necessary based on these lab values. Hyperlipidemia is also a concern, but neutropenia and LFT elevations are key monitoring parameters that can lead to immediate changes in therapy.
CSP - Certified Specialty Pharmacist Clinical Management: Immunology Questions and Answers
A patient with rheumatoid arthritis, who has failed methotrexate monotherapy, is being started on a Janus kinase (JAK) inhibitor.
Which of the following represents a class-wide black box warning for JAK inhibitors that the specialty pharmacist must counsel the patient on?